1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • December 2015
  • -
  • Firstword Pharma

Pipeline drugs are poised to reshape the way doctors treat ulcerative colitis (UC). But where will new therapies fit into the UC treatment paradigm? How will they affect existing brands? And what will it all mean for patients?
Get the answers in FirstWord’s KOL Insight: Ulcerative Colitis report. This 104 page report gives you an in-depth account of how 12 key opinion leaders (KOLs) in the US and Europe see the UC landscape.
Get KOLs’ candid thoughts about how the UC treatment paradigm is changing, where pipeline drugs are likely to be positioned, and which clinical trials will have the greatest impact on important treatment decisions.

Answering Key Questions

Get answers to key questions about marketed and pipeline ulcerative colitis therapies:

Uceris, Cortiment: How are doctors using Uceris? What factors are affecting its uptake?
LT 02: Where in the early-to-moderate UC treatment paradigm do KOLs see LT02?
Anti-TNFs Inhibitors (Remicade, Humira, Simponi): How will biosimilars in the pipeline affect branded versions of these drugs?
Entyvio: Can first-to-market advantage help Entyvio stave off competition?
Etrolizumab: How will this pipeline integrin inhibitor be positioned?
AJM 300: Do KOLs expect orally administered integrin antagonists such as AJM 300 to be effective treatments?
Tofacitinib: Do KOLs have the information they need to position tofacitinib in the treatment paradigm?
Ozanimod: Which brands will compete with this oral pipeline therapy?
Kappaproct: How do KOLs view Kappaproct’s potential to treat moderate-to-severe-UC?
Alicaforsen: For which patient population are doctors most likely to use alicaforsen?

Top takeaways
The future of 5-ASAs: Find out whether 5-ASAs will remain the go-to treatment for mild-to-moderate UC
New mild-to-moderate UC treatments: Learn how pipeline drugs for mild-to-moderate UC will affect first-line treatment
Uceris in the treatment paradigm: Understand how doctors use Uceris, and find out whether they’re likely to expand its use in the future
Changes to integrin inhibitor use: Is the way doctors use Entyvio changing? See what that could mean for the UC treatment paradigm
Effect of new integrin inhibitors: Explore the impact of new integrin inhibitors—and other pipeline drugs—on Entyvio
Biosimilars in the anti-TNF market: Use of anti-TNFs is on the rise. Discover how biosimilars currently in the pipeline will affect the market
Oral therapies: Find out how new oral therapies will affect moderate-to-severe UC treatment

Key issues explored

Mild-to-moderate UC landscape: Will cheap, safe, and effective 5-ASAs continue to be the mainstay treatment? Which pipeline products will also be used for mild-to-moderate UC?
Moderate-to-severe UC landscape: How do KOLs expect the treatment paradigm to change as later-line therapies in the pipeline come to market?
Important clinical trials: Key clinical trials will affect important treatment decisions. Which trials are most important? Which brands are most affected?
Impact of biosimilars: As anti-TNF biosimilars come to market, how are branded drug makers likely to respond? What do KOLs think will drive biosimilar adoption?
Changing use of Entyvio: How is the way doctors use Entyvio likely to change? What role will pipeline products play?
Oral therapies on the way: KOLs think oral therapies will have a significant impact on UC treatment. How will they be positioned in the treatment paradigm, and why?
Potential of earlier-stage products: How do KOLs view the prospects of early-stage drugs such as Apremilast, Bertilimumab, and Mongersen?

A report based on expert knowledge

KOLs from North America
Prof Jean-Frédéric Colombel, MD. Professor of Medicine and Director of the Susan and Leonor Feinstein IBD Center, Icahn School of Medicine, New York, USA.
Dr Brian Behm, MD. Associate Professor of Medicine and Director of the Inflammatory Bowel Disease Program, University of Virginia, Virginia, USA.
Prof David Sachar, MD. Clinical Professor of Medicine and Director Emeritus of the GI Division, Mount Sinai School of Medicine, New York, USA.
Dr Joseph Feuerstein, MD. Gastroenterologist (Board Certified), Beth Israel Deaconess Medical Centre, Boston, USA.
Dr Suneeta Krishnareddy, MD. Gastroenterologist (Board Certified), faculty of Digestive and Liver Diseases, Columbia University Medical Center, New York, USA.
Prof Burton Korelitz, MD. Director for Clinical Research in Inflammatory Bowel Diseases, Lenox Hill Hospital, New York, USA.

KOLs from Europe
Dr SS Hoque. Consultant Physician and Gastroenterologist, Barts Health NHS Trust at Whipps Cross University Hospital, London, UK.
Dr Renato Caviglia, MD, Ph.D. Consultant, Department of Gastroenterology and Digestive Endoscopy, Ospedale Israelitico, Roma, Italy.
Dr Thierry Paupard. Head of the Gastroenterology, Centre Hospitalier de Dunkerque, Dunkerque, France.
German KOL. Expert in Crohn’s disease and ulcerative colitis, Germany.
German KOL. Chief and head of gastroenterology, hospital, Germany.
Dr Marcus Harbord. Consultant Physician and Gastroenterologist, Chelsea & Westminster Hospital, London, UK

Get KOL insights into

Therapies for Mild-to-moderate Ulcerative Colitis
Marketed Drugs:
Uceris, Cortiment (Budesonide MMX; Cosmo/Santarus/Ferring)
Pipeline Drugs:
LT 02 (phosphatidylcholine controlled-release; Lipid Therapeutics/Dr Falk Pharma/Nestlé Health Science)
Therapies for Moderate-to-Severe Ulcerative Colitis
Marketed Drugs:
Branded Anti-TNFs:
Remicade (Infliximab; Janssen Biotech/Merck & Co. /Mitsubishi Tanabe)
Humira (Adalimumab; AbbVie/Eisai)
Simponi (Golimumab; Janssen Biotech/Merck & Co.)
Anti-TNF Biosimilars
Remsima (Infliximab; Celltrion)
Inflectra (Infliximab; Hospira)
Entyvio (Vedolizumab; Millennium/Takeda.)

Pipeline Drugs:
Etrolizumab (RG 7413, rhuMab beta7; Roche)
AJM 300 (Ajinomoto/Kissei)
Tofacitinib (CP 690550; Pfizer)
Ozanimod (RPC 1063; Celgene)
Kappaproct (cobitolimod, DIMS 0150; InDex Pharmaceuticals)
Alicaforsen (ISIS 2302; Atlantic Healthcare/Isis Pharmaceuticals)

Ongoing Benefits

The world of pharma is ever changing and executives must always be up-to-date with new developments that could affect their own products, position and research. That is why FirstWord's guarantee to keep Therapy Trends clients up to date with Update Bulletins offers a real commercial advantage.
Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update
Your Therapy Trends Report purchase entitles you to receive three Update Bulletins, which are published approximately every three months for 12 months following the report's publication date, Dec 2015
You will receive a copy of each Update Bulletin once available, which are issued each quarter after the publication date.

Table Of Contents

Ulcerative Colitis: KOL Insight
1Executive summary 1
2Research Objectives 3
3Research Focus 5
4Mild-to-moderate UC 8
41Overview 8
42Marketed Drugs 9
43Uceris, Cortiment (Budesonide MMX; Cosmo/Santarus/Ferring) 9
44Pipeline Drugs 18
45LT 02 (phosphatidylcholine controlled-release; Lipid Therapeutics/Dr Falk Pharma/Nestle Health Science) 18
6Moderate-to-severe UC 25
61Overview 25
62Marketed Drugs 26
63TNF inhibitors (Remicade, Humira, Simponi) 26
64Entyvio (vedolizumab; Millennium/Takeda) 42
65Pipeline Drugs 55
66etrolizumab (RG 7413, rhuMab beta7; Roche) 55
67AJM 300 (Ajinomoto/Kissei) 63 tofacitinib (CP 690550; Pfizer) 67
68ozanimod (RPC 1063; Celgene) 75 Kappaproct (cobitolimod, DIMS 0150; InDex Pharmaceuticals) 80
69alicaforsen (ISIS 2302; Atlantic Healthcare/Isis Pharmaceuticals) 85
7Future developments in UC 89
71Apremilast approval in UC viewed as dubious 89
72Bertilimumab is not seen as a strong contender for UC 90
73Mongersen perceived to be the most exciting early-stage approach 91
74Current and future treatment algorithm 94
8Conclusion 96
9Appendix 97
91KOL biographies 97
92KOLs from North America 97
KOLs from Europe 99

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Hepatitis C: KOL Insight

Hepatitis C: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

As hepatitis C cures multiply, how do experts evaluate the options? Since the launch of Sovaldi (sofosbuvir; Gilead) in 2013, the hepatitis C (HCV) landscape has developed at a rapid pace. The focus ...

Chronic Lymphocytic Leukaemia: KOL Insight

Chronic Lymphocytic Leukaemia: KOL Insight

  • $ 8085
  • Industry report
  • August 2016
  • by Firstword Pharma

How will established and emerging agents reshape the CLL treatment landscape? How do key opinion leaders (KOLs) see the future treatment paradigm for chronic lymphocytic leukaemia (CLL) shaping up? Will ...

Prostate Cancer Pricing, Reimbursement, and Access

Prostate Cancer Pricing, Reimbursement, and Access

  • $ 7500
  • Industry report
  • July 2016
  • by Datamonitor Healthcare

Novel antiandrogens will need to present risk-sharing agreements in EU markets, while discussing contracting with US payers to ensure a competitive advantage. Vaccines suffer from inconclusive response ...

Download Unlimited Documents from Trusted Public Sources

Therapy Market in India

  • October 2016
    51 pages
  • Therapy  

  • India  

View report >

Therapy Market in Europe and the Netherlands

  • October 2016
    7 pages
  • Therapy  

    Blood Supply  

  • Europe  

View report >

Anti-Infective Market in Europe

  • October 2016
    149 pages
  • Anti-Infective  

  • Europe  


View report >

Related Market Segments :



Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.